These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32970933)

  • 21. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
    Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
    Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    Aldea M; Lam L; Orillard E; Llacer Perez C; Saint-Ghislain M; Gravis G; Fléchon A; Roubaud G; Barthelemy P; Ricci F; Priou F; Neviere Z; Beaufils M; Laguerre B; Hardy AC; Helissey C; Ratta R; Borchiellini D; Pobel C; Joly F; Castro E; Thiery-Vuillemin A; Baciarello G; Fizazi K
    Eur J Cancer; 2021 Dec; 159():87-97. PubMed ID: 34742160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
    Wenzel M; Borkowetz A; Lieb V; Hoffmann MA; Borgmann H; Höfner T; Dotzauer R; Neuberger M; Worst TS; von Hardenberg J; Linxweiler J; Klümper N
    Urol Oncol; 2022 Dec; 40(12):538.e7-538.e14. PubMed ID: 36244915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
    Kellokumpu-Lehtinen PL; Marttila T; Jekunen A; Hervonen P; Klintrup K; Kataja V; Utriainen T; Luukkaa M; Leskinen M; Pulkkanen K; Kautio AL; Huttunen T
    Anticancer Res; 2020 Dec; 40(12):6915-6921. PubMed ID: 33288585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
    Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
    Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
    Kanao K; Ito T; Takahara K; Ando R; Yasui T; Shiroki R; Miyake H; Sumitomo M
    Jpn J Clin Oncol; 2019 Dec; 49(11):1043-1048. PubMed ID: 31369101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
    Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
    Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
    Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
    Song W; Kwon GY; Kim JH; Lim JE; Jeon HG; Il Seo S; Jeon SS; Choi HY; Jeong BC; Lee HM
    Oncotarget; 2016 Dec; 7(50):83735-83743. PubMed ID: 27863438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
    Miyoshi Y; Sakamoto S; Kawahara T; Uemura K; Yokomizo Y; Uemura H
    Urol Int; 2019; 103(3):279-284. PubMed ID: 31461725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
    BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
    Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
    Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Ito T; Kanao K; Takahara K; Ando R; Yasui T; Shiroki R; Sumitomo M; Miyake H
    Anticancer Res; 2019 Jun; 39(6):3089-3094. PubMed ID: 31177153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
    Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
    Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
    Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.